Multiple Sclerosis Can Befall Little Children Too
MedIndia - Chennai,India
Liam was one of the first of his age group to be tried with new drug Tysabri . This was recently approved by the National Institute for Health and Clinical ...
See all stories on this topic

From Smoking Boom, a Major Killer of Women

BlueRidgeNow.com - Hendersonville,NC,USA
Ms. Rommes has chronic obstructive pulmonary disease, or COPD, a progressive illness that permanently damages the lungs and is usually caused by smoking. ...
See all stories on this topic

New Step Towards Regenerating An Amputated Limb, Canada
Researchers at the Universite de Montreal have identified a cell signaling pathway[1] implicated in limb regeneration in axolotls; a salamander living in Mexican lakes with the unique ability of regenerating damaged or destroyed limbs.29 Nov 2007

Multiple Sclerosis Can Befall Little Children Too

Parents of 14-year-old Liam Kelly can vouch that children do indeed get multiple sclerosis (MS). Liam has been suffering from the disorder for ten years now.
It started when the boy was four. All of a sudden his body became sore to the touch and then , he was unable to walk. In spite of this it was not until another year and relapse before he was diagnosed with MS.
"We went to the hospital and he was just screaming if anyone touched him. "The doctors said they did not know what it was”, recalls his father John. "I was horrified when I first got the diagnosis. I thought he was going to die, I thought it was final. "People say 'children don't get MS', but I am sorry they do”, says John.
This fact is supported by the MS Society. They say there is a misconception that MS does not occur in children. Research suggests there could be thousands of children with MS in the UK, the society informs.
It was to bring this fact to light that the MS Society held a conference this month having 60 experts and families with children affected by MS.
Liam was one of the first of his age group to be tried with new drug Tysabri . This was recently approved by the National Institute for Health and Clinical Excellence (NICE) . It is thought to help slow the progression of MS. Liam is currently in good shape , at least for now. "No-one know what the future holds for Liam," says John.

Usually MS is diagnosed in adults aged between 20 and 40 . According to experts, women are three times more likely to be diagnosed than men. Recent studies suggest as many as 9,000 people having the condition could have started showing symptoms when younger than 16.

Evangeline Wassmer, a consultant pediatric neurologist at Birmingham Children's Hospital, emphasizes the importance of starting treatment as early as possible. "It is important to make an early diagnosis and initiate treatment so that these children can benefit from early treatment and an improved quality of life”, she says.
According to Jayne Spink, director of policy and research at the MS Society, there are potentially thousands of children living with MS whose symptoms are not being recognized.
"Without better awareness of childhood MS these children could face years of care that fails to meet their needs, while their families are left in limbo. "In MS, early treatment improves your long-term prospects. It is vital that children with MS are not left out in the cold”, she says.
Source-Medindia
http://www.medindia.net/news/Multiple-Sclerosis-Can-Befall-Little-Children-Too-29949-1.htm

active biotech to present at the rodman & renshaw 9th annual ...
Earthtimes - London,UK
... us. during the presentation, management will provide an update on the active biotech development program. the presentation will include laquinimod, ...
See all stories on this topic

Better Treatment For Bladder Problems In People With MS, UK
New research funded by the MS Society has shown that Botox injections to the bladder provide benefits for people with multiple sclerosis (MS) with sustained improvements to their overall quality of life.28 Nov 2007
Stem-Cell Therapies For Brain More Complicated Than Thought
An MIT research team's latest finding suggests that stem cell therapies for the brain could be much more complicated than previously thought.In a study published in the Public Library of Science (PloS) Biology on Nov.28 Nov 2007
Better Treatment For Bladder Problems In People With MS, UK
Medical News Today Wed, 28 Nov 2007 2:03 AM PST
New research funded by the MS Society has shown that Botox injections to the bladder provide benefits for people with multiple sclerosis (MS) with sustained improvements to their overall quality of life.Bladder problems are a common and disabling symptom of MS where both storage and emptying processes can be disrupted. [click link for full article]

MULTIPLE SCLEROSIS SOCIETY OF CANADA (ONTARIO DIVISION)2006
Registered Charity Information Return
for
MULTIPLE SCLEROSIS SOCIETY OF CANADA (ONTARIO DIVISION)

Basic Information Sheet Section A. Identification Section B. Directors/Trustees and Like Officials Section C. Programs and General Information Section D. Compensation Section E. Financial Information Section F. Other Required Information Section G. For Foundation Only

Section E. Financial Information

E1	Was the financial information reported below prepared on an accrual or cash basis?	4020	ACCRUAL
E2	Figures are shown to the nearest dollar.
	Assets
	Cash, bank accounts, and short-term investments	4100	$ 2,648,401
	Amounts receivable from non-arm's length parties	4110	$ 187,232
	Amounts receivable from all others.	4120	$ 655,761
	Investments in non-arm's length parties	4130
	Long-term investments	4140	$ 4,996,309
	Inventories	4150	$ 62,407
	Capital assets (at cost or fair market value)	4160	$ 237,896
	Other assets	4170	$ 90,127
	Total assets (add lines 4100 to 4170)	4200	$ 8,878,133
	Liabilities
	Accounts payable and accrued liabilities.	4300	$ 984,891
	Deferred revenue	4310	$ 483,822
	Amounts owing to non-arm's length parties	4320	$ 2,865,752
	Other liabilities	4330
	Total liabilities	4350	$ 4,334,465
	Amount included in lines 4150, 4160, and 4170 not used in charitable programs	4250
E3	Figures are shown to the nearest dollar.
	Revenue
	Total eligible amount of tax-receipted gifts	4500	$ 6,592,241
	Total amount received from other registered charities	4510	$ 1,920,233
	Total specified gifts included in line 4510	4520	$ 1,407,421
	Total enduring property included in line 4510	4525
	Total other gifts	4530	$ 1,138,944
	Revenue from federal government	4540	$ 19,408
	Revenue from provincial/territorial governments	4550	$ 2,816
	Revenue from municipal/regional governments	4560	$ 12,111
	Total revenue from government	4570	$ 34,335
	Interest and investment income	4580	$ 248,915
	Proceeds from disposition of assets
	· gross	4590
	· net	4600
	Rental income (land and buildings)	4610
	Memberships, dues, and association fees (non tax-receipted)	4620	$ 54,359
	Total revenue from fundraising	4630	$ 9,087,277
	Total revenue from sale of goods and services (except to government)	4640
	Other revenue	4650	$ 477,237
	Total revenue	4700	$ 19,553,541
	Expenditures (Enter all expenditures, whether or not on charitable programs)
	Advertising and promotion	4800	$ 2,841,299
	Travel and vehicle	4810	$ 183,116
	Interest and bank charges	4820	$ 105,393
	Licences, memberships, and dues	4830	$ 210,921
	Office supplies and expenses	4840	$ 1,129,583
	Occupancy costs	4850	$ 829,748
	Professional and consulting fees	4860	$ 451,650
	Education and training for staff and volunteers	4870	$ 58,244
	Salaries, wages, benefits, and honoraria	4880	$ 5,812,490
	Donated and purchased supplies and assets expensed for the fiscal period	4890	$ 475,330
	Amortization of capitalized assets	4900	$ 62,715
	Research grants and scholarships as part of charitable programs	4910
	Other expenditures	4920	$ 2,148,801
	Total expenditures before gifts to qualified donees	4950	$ 14,309,290
	Total charitable programs expenditures included in line 4950	5000	$ 5,550,206
	Total management and administration expenditures included in line 4950	5010	$ 1,062,817
	Total fundraising expenditures included in line 4950	5020	$ 7,568,534
	Total political activity expenditures included in line 4950	5030	$ 127,733
	Total other expenditures included in line 4950	5040
	Total gifts to qualified donees, excluding enduring property	5050	$ 2,961,311
	Total enduring property transferred to qualified donees (See the guide.)	5060
	Total specified gifts to qualified donees (See the guide.)	5070	$ 1,407,421
	Total expenditures (add lines 4950, 5050, 5060 and 5070)	5100	$ 18,678,022

http://www.cra-arc.gc.ca/ebci/haip/srch/sec/SrchInput05Render-e?bn=107746174RR0004&fpe=2006-08-31&formId=19&name=MULTIPLE+SCLEROSIS+SOCIETY+OF+CANADA+(ONTARIO+DIVISION)

Transplants without tears
Science Magazine (subscription) - USA
... multiple sclerosis, and lupus, in which traditional conditioning was considered too drastic. "it's an intriguing new approach," says stem cell biologist ...
See all stories on this topic

Transplants Without Tears

By Mitch Leslie
ScienceNOW Daily News
26 November 2007

A new treatment might allow patients to avoid some of the grueling side effects of bone marrow transplants. Researchers reported in the 23 November issue of Science that they can use a specific type of antibody to clear away old marrow stem cells in mice, allowing fresh ones to take their place. The discovery could allow patients to receive bone marrow without undergoing chemotherapy and other toxic procedures.

Bone marrow transplants can ameliorate diseases such as sickle cell anemia by replenishing hematopoietic stem cells (HSCs) that spawn white and red blood cells. But before they receive this marrow, patients must typically undergo conditioning, a course of chemotherapy (and sometimes radiation) that wipes out immune cells that might attack the transplants and eliminates the existing, faulty HSCs. However, conditioning also devastates stem cells throughout the body, triggering hair loss, diarrhea, mental decline, and other side effects.

Searching for a gentler approach, postdoc Deepta Bhattacharya and immunologist Irving Weissman of the Stanford University School of Medicine in Palo Alto, California, and colleagues dosed mice with an antibody that ties up c-kit, a receptor on the surface of HSCs that promotes their division and survival. The antibody sent the number of HSCs in the animals' bone marrow plunging by more than 98% after 8 days, the researchers report. That seemed to clear space for new cells to rebuild the animals' immune systems. Six months after a bone marrow transplant, 90% of one type of immune cell were derived from transferred HSCs, the team found.

Weissman envisions that an HSC-removing antibody will be part of a two-pronged attack on illnesses such as sickle cell anemia, severe combined immunodeficiency, aplastic anemia, and thalassemia. First, patients would receive antibodies to suppress immune cells that might reject a bone marrow transplant; such antibodies are already in use, although they can cause flulike symptoms and other side effects. Then, an HSC-deleting antibody would make room for new stem cells. Weissman cautions, however, that researchers need to find a human antibody that performs as well as the mouse version. But if successful, the strategy could eliminate the need for chemotherapy and radiation and allow transplants for diseases, such as type 1 diabetes, multiple sclerosis, and lupus, in which traditional conditioning was considered too drastic.

"It's an intriguing new approach," says stem cell biologist and clinician David Scadden of Harvard Medical School in Boston, Massachusetts. But stem cell biologist Kateri Moore of Mount Sinai School of Medicine in New York City questions whether the antibody removes all HSCs. She notes that even without a transplant, HSC numbers rebound in mice within about 3 weeks of an antibody dose. Any HSCs spared by the antibody, she warns, could compete with newcomers for space or even produce T cells that attack the transplants.

Related site

More information on bone marrow transplants
http://sciencenow.sciencemag.org/cgi/content/full/2007/1126/2

Heading home.
A glowing stem cell transplant searches out a place to settle down.

Credit: Deepta Bhattacharya, Agnieszka Czechowicz, and Irving Weissman

__________________________________
Science 23 November 2007:
Vol. 318. no. 5854, pp. 1296 - 1299
DOI: 10.1126/science.1149726

Reports

http://www.sciencemag.org/cgi/content/abstract/318/5854/1296

Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches -- Czechowicz et al. 318 (5854): 1296 -- Science

Agnieszka Czechowicz, Daniel Kraft, Irving L. Weissman,^*Deepta Bhattacharya

Upon intravenous transplantation, hematopoietic stem cells (HSCs) can home to specialized niches, yet most HSCs fail to engraft unless recipients are subjected to toxic preconditioning. We provide evidence that, aside from immune barriers, donor HSC engraftment is restricted by occupancy of appropriate niches by host HSCs. Administration of ACK2, an antibody that blocks c-kit function, led to the transient removal of >98% of endogenous HSCs in immunodeficient mice. Subsequent transplantation of these mice with donor HSCs led to chimerism levels of up to 90%. Extrapolation of these methods to humans may enable mild but effective conditioning regimens for transplantation.

Institute of Stem Cell Biology and Regenerative Medicine, Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.

These authors contributed equally to this work.

^* To whom correspondence should be addressed. E-mail: irv@stanford.edu

Read the Full Text

--------------------------------------------

a new hope for 'silent disease'
Waikato Times - Waikato,New Zealand
... breakthrough ms drug called tysabri. the drug is aimed at reducing relapses and slowing the progression of disability in relapsing ms. while mrs hebberd ...
See all stories on this topic

Hello Bill,

Thank you so much for your email. The enrollment criteria for the Phase I/II trial for Chondrogen allowed patients 18-60 years of age.

If you require any additional information or have any other questions, please don't hesitate to contact me.

Sincerely,

Erica

Erica Elchin

Phone: 443.545.1824
Fax: 443.545.1701
www.osiris.com

7015 Albert Einstein Drive
Columbia, MD 21046

________

Migraine Linked to Structural Brain Changes

Ahead of the Bell: Lazard's Health Picks
CNNMoney.com - USA
Analyst Joel Sendek said there is a substantial market for biotechnology company Acora Therapeutics Inc'sa Fampridine-SR beyond its use for walking ...
See all stories on this topic

Change of Constitution
Sydney Morning Herald - Sydney,New South Wales,Australia
Its lead drug, ATL1102, is in the advanced stages of a Phase 2a trial as a potential treatment for multiple sclerosis. Contact Information: Website: ...
See all stories on this topic

Cast Your Vote Today To Help Day Centre, UK
Medical News Today Tue, 27 Nov 2007 11:03 AM PST
The Bournemouth branch of the MS Society is urging people to pick up the phone and show their support for a project that could receive almost £100,000 and benefit people with multiple sclerosis (MS) across the region. [click link for full article]

Cast Your Vote Today To Help Day Centre, UK
The Bournemouth branch of the MS Society is urging people to pick up the phone and show their support for a project that could receive almost £100,000 and benefit people with multiple sclerosis (MS) across the region.

Remoulding Attitudes Toward Disability, UK
The MS Society has given its full support to a unique campaign launched by Leonard Cheshire Disability, which aims to challenge and change people's attitudes toward disability.The disability charity has teamed up with Aardman Animations to create Creature Discomforts, based on the much-loved Creature Comforts series but featuring the hallmark Plasticine characters voiced by people with disabilities including multiple sclerosis (MS).

Research Breakthrough Changes Ethics of Stem Cell Debate
CU Columbia Spectator - New York,NY,USA
Piggybacking on the work of two researchers from Kyoto University who this summer turned mice's skin cells into stem cells, two groups from Japan and the ...
See all stories on this topic

Osiris Therapeutics Announces Positive One Year Data from ...
Business Wire (press release) - San Francisco,CA,USA
Chondrogen is a preparation of mesenchymal stem cells specifically formulated for direct injection into the knee. The stem cells are obtained from the bone ...
See all stories on this topic

Young singer with Parkinson's to sing for research benefit
Jerusalem Post - Israel
"Promoting stem cell research can contribute to solutions for this disease and others such as multiple sclerosis (MS) and amyotropic lateral sclerosis (ALS) ...
See all stories on this topic

Pedophiles have less brain white matter: Toronto study
http://www.cbc.ca/health/story/2007/11/28/pedophiles-study.html

Young MS sufferer wins backing of Les Ferdinand
ChronicleLive - Newcastle upon Tyne,England,UK
Patsy, now 15 and a pupil at Gateshead's Thomas Hepburn School, is the only person under 18 to try out the MS drug Campath. She lives with parents, ...
See all stories on this topic

Immune System Reboot Could Treat Autoimmune Disease
Wired News - USA
With the help of an ingenious protein hack, scientists have used stem cells to grow new immune systems in mice -- a technique that could someday treat human ...
See all stories on this topic

Stem Cell Transplants Have Grown New Immune Systems in Certain Mice
Associated Content - Denver,CO,USA
Autoimmune diseases like multiple sclerosis cause the immune system to become defective and it then attacks the persons own body. ...
See all stories on this topic

Nick Masullo's Journey With Multiple Sclerosis Inspires Community
Springdale Morning News - Springdale,AR,USA
Masullo has primary progressive MS, a rare form of the disease. In a few short years, he's gone from able-bodied to quadriplegic, requiring assistance to ...
See all stories on this topic

'My son was four when he developed MS'
BBC News - UK
Liam was one of the first of his age group to be put forward for a new drug Tysabri - recently approved by the National Institute for Health and Clinical ...
See all stories on this topic

Cell transplant hope for blood diseases
Telegraph.co.uk - United Kingdom
Using the same method, it should be possible to treat a person with an autoimmune disease, such as multiple sclerosis, in which immune cells attack the ...
See all stories on this topic

bioms medical achieves enrollment milestone in us phase iii ...
PharmaLive.com (press release) - Newtown,PA,USA
... in its maestro-03 us pivotal phase iii clinical trial of mbp8298 for the treatment of secondary progressive multiple sclerosis (spms). an interim safety ...
See all stories on this topic

Stanford researchers say new stem cell method has promise
Media Newswire (press release) - New York,NY,USA
Stem cells created from the cells of a person with multiple sclerosis, for example, could provide researchers with a way of understanding how that disease ...
See all stories on this topic

Hope for safer bone marrow transplants
... and regenerative medicine reasoned it might be possible to perform bone marrow transplants without needing risky therapy beforehand. In theory, it would allow doctors to treat auto-immune disorders such as multiple sclerosis, ...
Stu's Views and MS Related News - http://msviewsandrelatednews.com/blog5/

Stem cell transplant can grow new immune system in certain mice ...
By News Account
Many aspects of the technique would need to be adapted before it can be tested in humans, said Irving Weissman, MD, a co-senior author of the study and director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. ...
Scientific Blogging - The world's... - http://www.scientificblogging.com

Stem cell hope for immune disease via BBC News
"It is essentially a surgical strike against the blood-forming stem cells," said study author Dr Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. He added that he believed the hurdles ...
The Andy Blog - http://blog.andy.org.mx/

Stem cell hope for immune disease

Bone marrow stem cells are able to form new blood and immune cells

Common immune system disorders, such as multiple sclerosis and arthritis, could one day be treatable with bone marrow transplants, research suggests.

Currently, the procedure is reserved for life-threatening disorders because chemotherapy or radiotherapy is needed before a transplant can be done.

But a protein may do the same job without dangerous side-effects, a mouse study published in Science suggests.

However, the technique is not yet ready for testing in humans.

Stem cell studies are an important avenue of research which hold promise in terms of treatments for MS

Dr Laura Bell, MS Society

The purpose of a bone marrow transplant is to infuse the body with healthy adult stem cells which are able to form fresh blood and immune cells.

In order for the new blood-forming stem cells to take hold, the faulty cells in the bone marrow must first be destroyed, but the aggressive therapies used can cause severe side effects, such as brain damage, increased risk of cancer or infertility.

A person with an autoimmune disease such as multiple sclerosis has a defective immune system in which immune cells attack the person's own body.

Treatment with a bone marrow transplant would give the patient an immune system that might not attack the body, but this could only be done if the technique was less dangerous.

Antibodies

A team from Stanford University in the US found that injecting mice with antibodies which latch on to specific proteins on the surface of blood-forming stem cells, destroyed the cells without harming the mice.

Blood-forming stem cells transplanted into the mice were then able to take up residence in the bone marrow and set up a new blood and immune system.

However, the barriers are still significant, the researchers said, as the work was done on a particular group of mice that are a poor mimic for the human immune system.

And it remains to be seen whether the same molecule on human blood-forming stem cells would be the right one to use.

"It is essentially a surgical strike against the blood-forming stem cells," said study author Dr Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

He added that he believed the hurdles to translating the research into humans could be overcome.

Dr Laura Bell, research communications officer at the MS Society, said: "Stem cell studies are an important avenue of research which hold promise in terms of treatments for MS.

"This early stage study is interesting and we look forward to seeing how the work translates into studies in people with MS."
http://news.bbc.co.uk/2/hi/health/7108877.stm

Stem Cell Transplant Can Grow New Immune System In Certain Mice ...
Science Daily (press release) - USA
A person with an autoimmune disease such as multiple sclerosis has a defective immune system in which immune cells attack the person's own body. ...
See all stories on this topic

Stem cell hope for immune disease
By Luu Hieu(Luu Hieu)
"It is essentially a surgical strike against the blood-forming stem cells," said study author Dr Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. He added that he believed the hurdles ...
Welcome to LHTH Blog! - http://lhthieu.blogspot.com/ StreetInsider.com - New Report Analyzes Key Controversies in ...
Intriguing neuroprotection / neuroregeneration strategies, including LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb. ...

CBC.ca - Mansbridge One on One
RICHARD SMITH

Richard Smith

Author, The Trouble with Medical Journals
Former editor, British Medical Journal

November 24, 2007

http://www.cbc.ca/mansbridge/
Stem cell hope for immune disease
BBC News Fri, 23 Nov 2007 4:25 AM PST
Bone marrow transplants may one day be used to treat multiple sclerosis and arthritis, research suggests.

elan losses narrow as tysabri sales grow
Forbes - NY,USA
... lower third-quarter losses thursday and a sales milestone for its key product, the multiple sclerosis treatment tysabri. for the july-september quarter, ...
See all stories on this topic

Could you be the next Marketocracy investment expert?
Times Online - UK
A third of them responded, explaining that the shares had tumbled more than 90 per cent after the company's product Tysabri, a multiple sclerosis (MS) drug, ...
See all stories on this topic

Minocycline May Have A Negative Effect In Some Neurological Conditions
New research published in the journal The Lancet Neurology has shown that the drug minocycline may have a harmful effect in people with Amyotrophic lateral sclerosis (ALS) according to one of the first randomised trials in people with a neurological disorder.
19 Nov 2007

Further Evidence To Link EBV Virus Infection With MS, UK
New research published in The Journal of Experimental Medicine has provided more evidence that a common human virus called Epstein Barr Virus (EBV) plays an important role in the development of MS.
19 Nov 2007

Stem cell hope for immune disease
BBC News - UK
Common immune system disorders, such as multiple sclerosis and arthritis, could one day be treatable with bone marrow transplants, research suggests. ...
See all stories on this topic

Hope for safer bone marrow transplants
By Rockefeller Medical Library(Rockefeller Medical Library)
... such as multiple sclerosis and rheumatoid arthritis could one day be treated with bone marrow transplants, scientists claimed yesterday. Researchers at Stanford University's institute for stem cell biology and regenerative medicine ...
NeuroInfo - http://neurolib.blogspot.com/

Helio Therapy And Your Mental Well Being
By admin
The multiple sclerosis patient studies show that people in the light of the sun areas are less dependent on multiple sclerosis. For example, the Norwegians, which is near the sea and consume seafood enriched with Vitamin E, ...
Test Blog Title - http://members.lycos.co.uk/dfsdw

[StemCells] Growing new immune system (MS Diabetes ) in mice (for now)
By Manoj Kumar Valluru(Manoj Kumar Valluru)
Institute for Stem Cell Biology and Regenerative Medicine. The work was done on a particular group of mice that are a poor mimic for the human immune system. Still, Weissman suggested the remaining hurdles could eventually be overcome. ...
Stem Cell - http://stemcellbiology.blogspot.com/

Scientists close in on creating new immune system using stem cells
By admin
However, Irving Weissman, MD, a co-senior author of the study and director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine said that many aspects of the technique would need to be adapted before it can be ...
IndiBlitz.com - http://www.indiblitz.com/

Growing New Immune System Following Stem Cell Transplant In Mouse ...
By Mallows
Many aspects of the technique would need to be adapted before it can be tested in humans, said Irving Weissman, MD, a co-senior author of the study and director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. ...
Medical News and Health News Blog - http://www.medicalnewsblog.info

(long post, flee while you can)
Democratic Underground - Washington,DC,USA
This disease has no cure, but there are a lot of people in medical research spheres who think stem cell therapy holds great promise for either a full cure, ...
See all stories on this topic

BioMS Medical

BioMS Medical
http://www.biomsmedical.com/
Video
http://www.wallstreetreporter.com./page.php?page=view_videos&id=122

Wall Street Reporter Features Exclusive Video Interviews with ... CNNMoney.com - USA The only Phase III study with a novel therapeutic for Secondary Progressive Multiple Sclerosis in the world. * The large patient population and lack of ... See all stories on this topic BioMS Medical Corp. TSX: MS
Interview with: Kevin Giese President and Chief Executive Officer

Add to your social bookmarks :

Save to My Web

• Reviews/Comments

There are no comments on this interview, be the first to post a comment.

What do you think ? Post your comments here !

Name :
Title :
Commnet :

---

• Corporate Info

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01.

Company Website

Markets Quote Depth/LII Options Charts News Profile Financials Insiders Filings Historical Symbol: MarketsDetailed QuoteDepth/LIIOptionsChartsNewsProfileFinancialsInsidersFilingsHistorical Symbol Lookup powered by quotemedia.com

Detailed Quote for Bioms Medical (MS:CA) $ 2.35 0.09 (+3.98%) Volume: 158.32 k 3:58 PM EST Nov 23, 2007 close 52 Week Information 52 Week High January 29,2007 Close: 4.29 52 Week Low August 16,2007 Close: 1.70 Today 5d 1m 3m 1y more Last Price 2.35 Change $ 0.09 Change % 3.98% Tick Bid 2.31 Bid Size 100 Ask 2.35 Ask Size 900 Open 2.22 High 2.38 Low 2.22 Prev Close 2.26 Last Trade 3:58 Volume 158.32 k 52 Wk Hi 4.29 52 Wk Low 1.70 Market Cap 214.69 m Ex-Div Date N/A Div Rate N/A Yield N/A Shares 91.36 m EPS (TTM) -0.66 PE Ratio N/A close Exchange Information Listed On Toronto Stock Exchange (TSX) Exchange TSX

News for Bioms Medical (MS:CA) Sector News | Topic News Sector News Basic Materials - Chemicals - Energy - Metals & Mining Conglomerates - Conglomerates Consumer Goods - Consumer Durables - Consumer Non-Durables - Automotive - Food & Beverage - Tobacco Financial - Banking - Financial Services - Insurance - Real Estate Healthcare - Drugs - Health Services Industrial Goods - Aerospace/Defense - Manufacturing - Materials & Construction Services - Leisure - Media - Retail - Specialty Retail - Wholesale - Diversified Services - Transportation Technology - Computer Hardware - Computer Software & Services - Electronics - Telecommunications - Internet Utilities - Utilities Hide Market News AMEX Nasdaq NYSE OTCBB Pink Sheets Mutual Funds Commodities TSX World Market News Asia Pacific Europe Corporate Actions Stock Buyback Dividends Earnings Stock Splits Insider Trading IPO's Business & Finance Antitrust Banking & Finance Capital Gains Mergers & Acquisitions Economy Consumer Price Index Bond/Stock Update Federal Reserve Foreign Exchange International Monetary Fund Interest Rates Hide Fri, Nov 23, 2007 5:00 AM Wall Street Reporter Features Exclusive Video Interviews with CEO's of BioMS Medical Corp., RegeneRx Biopharmaceuticals, Inc., and Canopus BioPharma - PrimeNewswire Wed, Nov 14, 2007 5:00 PM BioMS Medical announces third quarter 2007 results - PR Newswire 5:00 PM BioMS Medical announces third quarter 2007 results - Canada NewsWire Mon, Nov 12, 2007 8:02 AM BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial - PR Newswire 8:00 AM BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial - Canada NewsWire Thu, Nov 08, 2007 8:00 AM BioMS Medical Corp.-Webcast Alert: Biotech/Pharma/Healthcare On-line Forum - CCN Matthews Wed, Nov 07, 2007 9:13 AM BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board - PR Newswire 9:13 AM BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board - Canada NewsWire Wed, Oct 31, 2007 7:00 AM BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference - PR Newswire 7:00 AM BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference - Canada NewsWire

More News for MS:CA More Filings for MS:CA

Copyright © QuoteMedia. Data delayed 15 to 20 minutes unless otherwise indicated. RT Realtime, EOD End Of Day, PD Previous Day. Market Data powered by QuoteMedia, fundamentals by Hemscott. Terms of Use.

http://www.wallstreetreporter.com./page.php?page=view_videos&id=१२२

Wall Street Reporter Features Exclusive Video Interviews with ...
CNNMoney.com - USA
The only Phase III study with a novel therapeutic for Secondary Progressive Multiple Sclerosis in the world. * The large patient population and lack of ...
See all stories on this topic

Moving On' from Stigma
Derry Journal - Derry,Northern Ireland,UK
Although, I would not necessarily say this of Primary Progressive MS from which thankfully, I was spared. And to the lady who knocked me and my zimmer frame ...
See all stories on this topic

(MS) Multiple Sclerosis Treatment with Alternative Medicine ...
By gwenniegrelck
By Brent Atwater Montel Williams called it an insidious disease. Richard Pryor passed away with its complications, and Michael Wellford, when diagnosed, just said "I'm NOT having it!" Multiple Sclerosis or MS is a slow progressing ...
the gwennie grelck - http://gwenniegrelck.wealog.com

active biotech's election committee appointed
Genetic Engineering News (press release) - New Rochelle,NY,USA
... advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, ...
See all stories on this topic

Teenage MS sufferer is to be model for national charity
ChronicleLive - Newcastle upon Tyne,England,UK
And the pupil at Gateshead's Thomas Hepburn School is the only person under 18 to try out the MS wonder drug Campath. Patsy lives with her parents, ...
See all stories on this topic

genzyme reports strong earnings growth in third quarter
Oxfordshire Bioscience Network (press release) - Oxford,UK
--the fda approved expanded labeling for campath® (alemtuzumab) to include first-line treatment of b-cell chronic lymphocytic leukemia, ...
See all stories on this topic